A detailed history of Wells Fargo & Company transactions in Equillium, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 1,000 shares of EQ stock, worth $610. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 1,000 -0.0%
Holding current value
$610
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.66 - $2.33 $99 - $351
-151 Reduced 13.12%
1,000 $0
Q1 2024

May 10, 2024

BUY
$0.73 - $3.0 $1 - $6
2 Added 0.17%
1,151 $2,000
Q4 2023

Feb 09, 2024

BUY
$0.48 - $0.74 $4 - $7
10 Added 0.88%
1,149 $0
Q3 2023

Nov 13, 2023

BUY
$0.72 - $0.9 $2 - $2
3 Added 0.26%
1,139 $0
Q2 2023

Aug 15, 2023

BUY
$0.49 - $0.79 $2 - $3
5 Added 0.44%
1,136 $0
Q1 2023

May 12, 2023

BUY
$0.56 - $1.24 $1 - $2
2 Added 0.18%
1,131 $0
Q4 2022

Feb 13, 2023

BUY
$0.83 - $2.26 $3 - $9
4 Added 0.36%
1,129 $1,000
Q3 2022

Nov 14, 2022

SELL
$1.93 - $3.14 $55 - $91
-29 Reduced 2.51%
1,125 $2,000
Q2 2022

Aug 12, 2022

BUY
$1.69 - $3.26 $70 - $136
42 Added 3.78%
1,154 $2,000
Q2 2021

Aug 16, 2021

SELL
$5.11 - $7.64 $5 - $7
-1 Reduced 0.09%
1,112 $7,000
Q1 2021

May 13, 2021

BUY
$5.03 - $10.5 $5,170 - $10,794
1,028 Added 1209.41%
1,113 $8,000
Q4 2020

Feb 09, 2021

BUY
$3.48 - $6.58 $20 - $39
6 Added 7.59%
85 $0
Q3 2020

Nov 05, 2020

SELL
$2.78 - $26.5 $5,429 - $51,754
-1,953 Reduced 96.11%
79 $0
Q2 2020

Aug 13, 2020

BUY
$2.34 - $3.53 $2,342 - $3,533
1,001 Added 97.09%
2,032 $6,000
Q1 2020

May 14, 2020

BUY
$2.3 - $5.5 $2,371 - $5,670
1,031 New
1,031 $3,000

Others Institutions Holding EQ

About Equillium, Inc.


  • Ticker EQ
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,352,100
  • Market Cap $21M
  • Description
  • Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...
More about EQ
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.